Currently predicting for Wed, 1 May 2024

Trading levels for SNDX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 21.78 2.35 %
R2 21.55 1.29 %
R1 21.42 0.636 %
Current price: 21.28
Support S1 20.96 -1.48 %
S2 20.83 -2.14 %
S3 20.60 -3.20 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 24.57 15.46 %
R2 23.52 10.53 %
R1 21.92 3.01 %
Current price 21.28
Support S1 20.74 -2.54%
S2 20.49 -3.71%
S3 20.32 -4.51%

SNDX Predictions History

4 years ago
JS predicted that SNDX for 2020-04-29 is going $18.30 (-2.14%)

4 years ago
Parisa Adl predicted that SNDX for 2020-04-29 is going $11.51 (-40.97%)

Rank:

4 years ago
JS predicted that SNDX for 2019-08-14 is going $11.16 (9.20%)

4 years ago
NameNotImportant predicted that SNDX for 2019-05-06 is going $7.32 (2.23%)

4 years ago
NameNotImportant predicted that SNDX for 2019-05-03 is going $7.12 (-0.56%)

5 years ago
NameNotImportant predicted that SNDX for 2019-04-24 is going $6.47 (-7.04%)

5 years ago
JS predicted that SNDX for 2018-09-05 is going $7.74 (-0.26%)

5 years ago
anand15 predicted that SNDX for 2018-09-05 is going $6.90 (-11.08%)

Rank:

5 years ago
JS predicted that SNDX for 2018-07-06 is going $7.26 (-0.95%)

Click to get the best stock tips daily for free!

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that b... SNDX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT